STON2

Across TCGA pan-cancer cohorts, STON2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STON2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STON2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STON2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where STON2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.893	0.602	.007	27	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.637	.010	22	view →
HNSC	DFS	Median	All	0.751	0.524	.002	17	view →
GBM	OS	Tertile	All	0.441	0.633	.014	8	view →
LUAD	OS	Median	III,IV	0.298	0.808	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STON2–CCRCC (DFS)

Open the CCRCC breakdown →